Success Metrics

Clinical Success Rate
94.7%

Based on 18 completed trials

Completion Rate
95%(18/19)
Active Trials
0(0%)
Results Posted
67%(12 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_4
1
5%
Ph phase_1
4
21%
Ph phase_3
8
42%
Ph phase_2
6
32%

Phase Distribution

4

Early Stage

6

Mid Stage

9

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
4(21.1%)
Phase 2Efficacy & side effects
6(31.6%)
Phase 3Large-scale testing
8(42.1%)
Phase 4Post-market surveillance
1(5.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.7%

18 of 19 finished

Non-Completion Rate

5.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

19

all time

Status Distribution
Completed(18)
Terminated(1)

Detailed Status

Completed18
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
0
Success Rate
94.7%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (21.1%)
Phase 26 (31.6%)
Phase 38 (42.1%)
Phase 41 (5.3%)

Trials by Status

terminated15%
completed1895%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT04147208Phase 2

Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

Completed
NCT04551261Phase 1

GLS4/RTV and TAF Drug-drug Interaction

Completed
NCT01815736Phase 3

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

Completed
NCT03472326Phase 2

Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus

Terminated
NCT02603107Phase 3

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

Completed
NCT03638076Phase 2

The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules

Completed
NCT02652624Phase 3

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

Completed
NCT03662568Phase 1

A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects

Completed
NCT01705574Phase 3

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

Completed
NCT02246998Phase 4

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

Completed
NCT01475838Phase 3

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Completed
NCT01108510Phase 3

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Completed
NCT00445146Phase 2

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

Completed
NCT00892437Phase 2

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Completed
NCT01907724Phase 1

Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)

Completed
NCT01252940Phase 3

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

Completed
NCT02248883Phase 1

Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects

Completed
NCT02187107Phase 2

A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials

Completed
NCT00272779Phase 3

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

Completed

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19